Albumin fusion of thioredoxin - The production and evaluation of its biological activity for potential therapeutic applications

Journal of Controlled Release

Volumn 147, Issue 1, 2010, Pages 17-23

  Ikuta, Shotaro ^a   Chuang, Victor Tuan Giam ^a,b,c   Ishima, Yu ^a   Nakajou, Keisuke ^a   Furukawa, Masato ^a   Watanabe, Hiroshi ^a   Maruyama, Toru ^a   Otagiri, Masaki ^a,b  

^a KUMAMOTO UNIVERSITY   (Japan)

^b SOJO UNIVERSITY   (Japan)

^c CURTIN UNIVERSITY   (Australia)

Author keywords

Endotoxic shock; Fusion protein; Human serum albumin; Pharmacodynamic; Pharmacokinetic; Recombinant albumin; Thioredoxin

Indexed keywords

ENDOTOXIC SHOCK; FUSION PROTEINS; HUMAN SERUM ALBUMIN; RECOMBINANT ALBUMIN; THIOREDOXINS;

BODY FLUIDS; PHARMACOKINETICS;

PROTEINS;

ALBUMIN; GALACTOSAMINE; HUMAN SERUM ALBUMIN; HYBRID PROTEIN; INDIUM 111; INSULIN; LIPOPOLYSACCHARIDE; THIOREDOXIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CIRCULAR DICHROISM; CONTROLLED STUDY; DRUG ACCUMULATION; DRUG ACTIVITY; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG MANUFACTURE; DRUG SCREENING; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG TISSUE LEVEL; ISOTOPE LABELING; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; SEPTIC SHOCK; SURVIVAL RATE;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; BLOTTING, WESTERN; CIRCULAR DICHROISM; DISEASE MODELS, ANIMAL; DRUG STABILITY; ELECTROPHORESIS, POLYACRYLAMIDE GEL; ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMANS; MALE; MICE; MICE, INBRED STRAINS; PICHIA; PROTEIN CONFORMATION; RECOMBINANT FUSION PROTEINS; SERUM ALBUMIN; SHOCK, SEPTIC; SURVIVAL ANALYSIS; THIOREDOXINS; TISSUE DISTRIBUTION;

EID: 80052260642     PISSN: 01683659     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jconrel.2010.05.020     Document Type: Article

References (28)

1. Arner E.S., Holmgren A. Physiological functions of thioredoxin and thioredoxin reductase. Eur. J. Biochem. 2000, 267:6102-6109.
2. Tao L., Gao E., Bryan N.S., Qu Y., Liu H.R., Hu A., Christopher T.A., Lopez B.L., Yodoi J., Koch W.J., Feelisch M., Ma X.L. Cardioprotective effects of thioredoxin in myocardial ischemia and reperfusion: role of S-nitrosation. Proc. Natl Acad. Sci. USA 2004, 101:11471-11476.
3. Hattori I., Takagi Y., Nakamura H., Nozaki K., Bai J., Kondo N., Sugino T., Nishimura M., Hashimoto N., Yodoi J. Intravenous administration of thioredoxin decreases brain damage following transient focal cerebral ischemia in mice. Antioxid. Redox Signal. 2004, 6:81-87.
4. Liu W., Nakamura H., Shioji K., Tanito M., Oka S., Ahsan M.K., Son A., Ishii Y., Kishimoto C., Yodoi J. Thioredoxin-1 ameliorates myosin-induced autoimmune myocarditis by suppressing chemokine expressions and leukocyte chemotaxis in mice. Circulation 2004, 110:1276-1283.
5. Hoshino T., Nakamura H., Okamoto M., Kato S., Araya S., Nomiyama K., Oizumi K., Young H.A., Aizawa H., Yodoi J. Redox-active protein thioredoxin prevents proinflammatory cytokine- or bleomycin-induced lung injury. Am. J. Respir. Crit. Care Med. 2003, 168:1075-1083.
6. Nakamura H., Hoshino Y., Okuyama H., Matsuo Y., Yodoi J. Thioredoxin 1 delivery as new therapeutics. Adv. Drug Deliv. Rev. 2009, 61:303-309.
7. Hoshino Y., Shioji K., Nakamura H., Masutani H., Yodoi J. From oxygen sensing to heart failure: role of thioredoxin. Antioxid. Redox Signal. 2007, 9:689-699.
8. Nakamura T., Hoshino Y., Yamada A., Teratani A., Furukawa S., Okuyama H., Ueda S., Wada H., Yodoi J., Nakamura H. Recombinant human thioredoxin-1 becomes oxidized in circulation and suppresses bleomycin-induced neutrophil recruitment in the rat airway. Free Radic. Res. 2007, 41:1089-1098.
9. Chuang V.T., Otagiri M. Recombinant human serum albumin. Drugs Today 2007, 43:547-561.
10. Chuang V.T., Kragh-Hansen U., Otagiri M. Pharmaceutical strategies utilizing recombinant human serum albumin. Pharm. Res. 2002, 19:569-577.
11. Tomkin G.H. Albiglutide, an albumin-based fusion of glucagon-like peptide 1 for the potential treatment of type 2 diabetes. Curr. Opin. Mol. Ther. 2009, 11:579-588.
12. Rustgi V.K. Albinterferon alfa-2b, a novel fusion protein of human albumin and human interferon alfa-2b, for chronic hepatitis C. Curr. Med. Res. Opin. 2009, 25:991-1002.
13. Holmgren A. Thioredoxin catalyzes the reduction of insulin disulfides by dithiothreitol and dihydrolipoamide. J. Biol. Chem. 1979, 254:9627-9632.
14. Hnatowich D.J., Layne W.W., Childs R.L. The preparation and labeling of DTPA-coupled albumin. Int. J. Appl. Radiat. Isot. 1982, 33:327-332.
15. Watanabe H., Yamasaki K., Kragh-Hansen U., Tanase S., Harada K., Suenaga A., Otagiri M. In vitro and in vivo properties of recombinant human serum albumin from Pichia pastoris purified by a method of short processing time. Pharm. Res. 2001, 18:1775-1781.
16. Subramanian G.M., Fiscella M., Lamousé-Smith A., Zeuzem S., McHutchison J.G. Albinterferon alpha-2b: a genetic fusion protein for the treatment of chronic hepatitis C. Nat. Biotechnol. 2007, 25:1411-1419.
17. Ueda S., Nakamura T., Yamada A., Teratani A., Matsui N., Furukawa S., Hoshino Y., Narita M., Yodoi J., Nakamura H. Recombinant human thioredoxin suppresses lipopolysaccharide-induced bronchoalveolar neutrophil infiltration in rat. Life Sci. 2006, 79:1170-1177.
18. Nakamura H., Herzenberg L.A., Bai J., Araya S., Kondo N., Nishinaka Y., Yodoi J. Circulating thioredoxin suppresses lipopolysaccharide-induced neutrophil chemotaxis. Proc. Natl Acad. Sci. USA 2001, 98:15143-15148.
19. Duttaroy A., Kanakaraj P., Osborn B.L., Schneider H., Pickeral O.K., Chen C., Zhang G., Kaithamana S., Singh M., Schulingkamp R., Crossan D., Bock J., Kaufman T.E., Reavey P., Carey-Barber M., Krishnan S.R., Garcia A., Murphy K., Siskind J.K., McLean M.A., Cheng S., Ruben S., Birse C.E., Blondel O. Development of a long-acting insulin analog using albumin fusion technology. Diabetes 2005, 54:251-258.
20. Melder R.J., Osborn B.L., Riccobene T., Kanakaraj P., Wei P., Chen G., Stolow D., Halpern W.G., Migone T.S., Wang Q., Grzegorzewski K.J., Gallant G. Pharmacokinetics and in vitro and in vivo anti-tumor response of an interleukin-2-human serum albumin fusion protein in mice. Cancer Immunol. Immunother. 2005, 54:535-547.
21. Huang Y.S., Chen Z., Chen Y.Q., Ma G.C., Shan J.F., Liu W., Zhou L.F. Preparation and characterization of a novel exendin-4 human serum albumin fusion protein expressed in Pichia pastoris. J. Pept. Sci. 2008, 14:588-595.
22. Muller D., Karle A., Meissburger B., Hofig I., Stork R., Kontermann R.E. Improved pharmacokinetics of recombinant bispecific antibody molecules by fusion to human serum albumin. J. Biol. Chem. 2007, 282:12650-12660.
23. Sano H., Sata T., Nanri H., Ikeda M., Shigematsu A. Thioredoxin is associated with endotoxin tolerance in mice. Crit. Care Med. 2002, 30:190-194.
24. Meziani F., Kremer H., Tesse A., Baron-Menguy C., Mathien C., Mostefai H.A., Carusio N., Schneider F., Asfar P., Andriantsitohaina R. Human serum albumin improves arterial dysfunction during early resuscitation in mouse endotoxic model via reduced oxidative and nitrosative stresses. Am. J. Pathol. 2007, 171:1753-1761.
25. Yoshida M., Akaike T., Wada Y., Sato K., Ikeda K., Ueda S., Maeda H. Therapeutic effects of imidazolineoxyl N-oxide against endotoxin shock through its direct nitric oxide-scavenging activity. Biochem. Biophys. Res. Commun. 1994, 202:923-930.
26. Haendeler J., Hoffmann J., Tischler V., Berk B.C., Zeiher A.M., Dimmeler S. Redox regulatory and anti-apoptotic functions of thioredoxin depend on S-nitrosylation at cysteine 69. Nat. Cell Biol. 2002, 4:743-749.
27. Hashemy S.I., Holmgren A. Regulation of the catalytic activity and structure of human thioredoxin 1 via oxidation and S-nitrosylation of cysteine residues. J. Biol. Chem. 2008, 283:21890-21898.
28. Tao L., Gao E., Hu A., Coletti C., Wang Y., Christopher T.A., Lopez B.L., Koch W., Ma X.L. Thioredoxin reduces post-ischemic myocardial apoptosis by reducing oxidative/nitrative stress. Br. J. Pharmacol. 2006, 149:311-318.